If you have been reading about Dual agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
== Medical uses == Isavuconazonium is used to treat invasive aspergillosis and invasive mucormycosis in adults aged eighteen years and older. It is available in a capsule for administration by mouth and as a powder for administration via infusion.
Morales even threatened to denounce Peru before the International Court of Justice in The Hague, because the Peruvian government granted diplomatic asylum to three former ministers of former President Sánchez de Losada, whom Morales described as "criminals", which he later It provoked anti-Peruvian marches in the city of El Alto by leftist movements and sindicalist, who threatened to expel all Peruvian citizens from the country and vandalize the Peruvian consulate if the former ministers' asylum is not revoked. On the other hand, Morales also accused Peru of wanting to "appropriate" the "cultural expressions" of Bolivia, to the point that the Bolivian Minister of Culture, Pablo Groux, threatened to take the dispute to the International Court of Justice in The Hague because they postulate that the diablada is native to Bolivia and not to Peru. In the following 5 years there were approximately ten complaints of appropriation of Bolivian folklore. The issue came to touch the national pride of both countries and fueled an anti-Peruvian position in several Bolivian nationalists opposed proposals to consider them bi-national. In addition, Evo went so far as to affirm that the demand of Peru in The Hague against Chile, due to the maritime delimitation controversy between the two countries, had the objective of blocking Bolivian aspirations for an outlet to the sea (through a corridor on the land border between Peru and Chile), stating that he had information in which the Peruvian Government "knows that the lawsuit is going to lose it.
== Society and culture == Some commentators argue that skin cancer surgery, including Mohs surgery, is overutilised as rates of skin cancer surgery are increasing worldwide. It is unclear if this relates to higher rates of skin cancer, increased vigilance in diagnosis, and increased availability of the procedure, or patient and doctor preferences. The incidence of Mohs surgery increased significantly over the decade between 2004 and 2014. In a sample of 100 Mohs surgeries, the total cost ranged from US$474 to US$7,594, with the higher costs for hospital-based complex procedures. In Australia, the direct out of pocket cost to patients may vary from $0 to $4000. When the non-Mohs surgery is performed by multiple doctors including pathologists the costs may be increased further. This is especially true when the cancer is incompletely excised and requires repeat surgery.
=== Drying === Drying a textile involves evaporating the free water, resulting in a dry fabric to which no additional chemicals have been introduced The removal of the moisture from textiles has can be accomplished by either air-drying or freeze-drying the objects. The rate of evaporation during the air-drying process varies but can be controlled by altering the level of humidity, temperature, and air movement textile while during the treatment.
Sources: en.wikipedia.org
=== Distinct proteins are made under distinct settings === A cell may make different sets of proteins at different times or under different conditions, for example during development, cellular differentiation, cell cycle, or carcinogenesis. Further increasing proteome complexity, as mentioned, most proteins are able to undergo a wide range of post-translational modifications. Therefore, a "proteomics" study may become complex very quickly, even if the topic of study is restricted. In more ambitious settings, such as when a biomarker for a specific cancer subtype is sought, the proteomics scientist might elect to study multiple blood serum samples from multiple cancer patients to minimise confounding factors and account for experimental noise. Thus, complicated experimental designs are sometimes necessary to account for the dynamic complexity of the proteome.
=== Nazi experiments === The harmful effects of X-rays were recognized during the Nazism era. The function of the gonads (ovaries or testicles) was destroyed by ionizing radiation, leading to infertility. In July 1942, Heinrich Himmler (1900-1945) decided to conduct forced sterilization experiments at the Auschwitz-Birkenau concentration camp, which were carried out by Horst Schumann (1906-1983), previously a doctor in Aktion T4. Each test victim had to stand between two X-ray machines, which were arranged in such a way that the test victim had just enough space between them. Opposite the x-ray machines was a booth with lead walls and a small window. From the booth, Schumann could direct X-rays at the test victims' sexual organs without endangering himself. Human radiation castration experiments were also conducted in concentration camps under the direction of Viktor Brack (1904-1948). As part of the "Law for the Prevention of Hereditary Diseases," people were often subjected to radiation castration during interrogations without their knowledge. Approximately 150 radiologists from hospitals throughout Germany participated in the forced castration of approximately 7,200 people using X-rays or radium.
== Cleaning == Like all protein-based fibers (wool, silk), products made from vicuña wool must be cleaned by dry cleaning (water-free) or by hand in tepid water with a mild detergent. Detergents which contain bleach or enzymes (protein-degrading enzymes) are unsuitable, as they damage the hair structure. In the case of hydrophilic textiles, such as textiles made of wool, water contact can lead to thread shortening and thus to shrinkage of the textile due to swelling and the shrinkage that follows during drying. Shrinkage is intensified in clothes dryers. Due to a tendency to felting, textiles made of vicuña wool should not be wrung or rubbed, but can be dabbed.
=== Courier services === There are a large number of local and international courier companies operating in South Africa, delivering documents and parcels on-demand for individuals and commercial entities. These companies provide services such as domestic and international delivery, cross-border e-commerce logistics, customs clearance, freight forwarding, warehousing, distribution, and last-mile parcel delivery. Courier companies operating in SA include:
Acetaldehyde – While most of the acetaldehyde produce gets reduced to ethanol or is bound by sulfur dioxide, concentrations between 50 and 100 mg/L can remain in the wine. The flor yeast strains that produce the Spanish wine Sherry will produce higher amounts that contributes to the characterized "aldehydic" aromas of Sherries. In the presence of oxygen, yeast can convert some of the ethanol presence in the wine back into acetaldehyde creating oxidized aromas. Hydrogen sulfide – Often produced by yeast during fermentation because of a nitrogen deficiency in the must. This can be done by a reduction of sulfates or sulfites available in the must or by the decomposition of dead yeast cells by other yeast that releases sulfur-containing amino acids that are further broken down by the yeast. The latter often happens with wines that sit in contact with their lees for long periods of time between rackings. In the presence of alcohol, hydrogen sulfide can react with ethanol to form ethyl mercaptans and disulfides that contribute to off aromas and wine faults. Some commercial yeast strains, such as Montrachet 522 are known to produce higher levels of hydrogen sulfides than other strains, particularly if the must has some nutrient deficiencies. Pyruvic acid – Along with acetaldehyde, this compound can react with anthocyanins extracted from contact with grape skins to create a more stable color pigment (pyranoanthocyanin) that can enhance the color of some red wines. Various esters, ketones, lactones, phenols and acetals.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.